SPEVIGO (IV)
SAFETY DATA
Adverse events with SPEVIGO (IV)1,a
Selected adverse events occurring in ≥1% of the intravenous SPEVIGO group and more frequently than in the placebo group through Week 1 in subjects with generalized pustular psoriasis (GPP) flare (EFFISAYIL 1)1,a,b,c
| Adverse events, n (%) | SPEVIGO (IV) (n=35) | Placebo (n=18) |
|---|---|---|
| Asthenia and fatigue | 3 (9) | 1 (6) |
| Headache | 3 (9) | 1 (6) |
| Nausea | 2 (6) | 0 |
| Pruritus and prurigo | 2 (6) | 0 |
| Infusion site hematoma and bruising | 2 (6) | 0 |
| Urinary tract infection | 2 (6) | 0 |
| Bacteremia | 1 (3) | 0 |
| Bacteriuria | 1 (3) | 0 |
| Cellulitis | 1 (3) | 0 |
| Herpes dermatitis and oral herpes | 1 (3) | 0 |
| Upper respiratory tract infection | 1 (3) | 0 |
| Dyspnea | 1 (3) | 0 |
| Eye edema | 1 (3) | 0 |
| Urticaria | 1 (3) | 0 |
In EFFISAYIL 1, additional adverse events that occurred through Week 12 in subjects treated with 1 single dose of randomized SPEVIGO were mild to moderate infections: device-related infection (3%), subcutaneous abscess (3%), furuncle (3%), and influenza (3%).1
AE, adverse event; DRESS, drug reaction with eosinophilia and systemic symptoms; IV, intravenous; OL, open-label; RCTC, Rheumatology Common Toxicity Criteria; SAE, serious adverse event.
aAll AEs occurring between the start of treatment and the end of residual effect period (16 weeks after the placebo dose or last dose of SPEVIGO). AEs were coded using the Medical Dictionary for Regulatory Activities v23.1. AE severity was graded according to the RCTC v2.0. Pustular psoriasis was excluded as an AE from this safety analysis. Data set at Week 12 included patients randomized to SPEVIGO who received up to 3 doses of SPEVIGO and patients randomized to the placebo group who received OL SPEVIGO at or after Day 8. All AEs in the residual effect period are included.
SAEs – SPEVIGO (IV) at Week 1: DRESS, urinary tract infection, drug-induced hepatic injury (considered to be a systemic symptom of DRESS) and arthritis; SPEVIGO (IV) at Week 12: DRESS, urinary tract infection, drug-induced hepatic injury (considered to be a systemic symptom of DRESS), arthritis, worsening of chronic plaque psoriasis, influenza, and squamous cell carcinoma of skin.2
bPatients must have discontinued biologics, retinoids, methotrexate, and/or cyclosporine before receiving their first dose of SPEVIGO (IV) or placebo.2
cSPEVIGO (IV) treatment was administered as a single 900-mg dose by intravenous infusion.1